Recognising the potential of Aileron Therapeutics’ peptide stabilisation technology, Roche has entered into a collaborative agreement with the company to develop drug candidates against five disease targets. The potential value of the deal is US$1.1 B, including a guaranteed US$25 M in technology access fees and R&D support.